Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Bekaii-Saab T, et al. Among authors: saji m. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25. J Clin Oncol. 2011. PMID: 21519026 Free PMC article. Clinical Trial.
Phase II trial of sorafenib in metastatic thyroid cancer.
Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH. Kloos RT, et al. Among authors: saji m. J Clin Oncol. 2009 Apr 1;27(10):1675-84. doi: 10.1200/JCO.2008.18.2717. Epub 2009 Mar 2. J Clin Oncol. 2009. PMID: 19255327 Free PMC article. Clinical Trial.
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Lam ET, et al. Among authors: saji m. J Clin Oncol. 2010 May 10;28(14):2323-30. doi: 10.1200/JCO.2009.25.0068. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368568 Free PMC article. Clinical Trial.
KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity.
Stathatos N, Bourdeau I, Espinosa AV, Saji M, Vasko VV, Burman KD, Stratakis CA, Ringel MD. Stathatos N, et al. Among authors: saji m. J Clin Endocrinol Metab. 2005 Sep;90(9):5432-40. doi: 10.1210/jc.2005-0963. Epub 2005 Jul 5. J Clin Endocrinol Metab. 2005. PMID: 15998767
Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair.
Robb R, Yang L, Shen C, Wolfe AR, Webb A, Zhang X, Vedaie M, Saji M, Jhiang S, Ringel MD, Williams TM. Robb R, et al. Among authors: saji m. Clin Cancer Res. 2019 Aug 1;25(15):4749-4760. doi: 10.1158/1078-0432.CCR-18-3625. Epub 2019 May 16. Clin Cancer Res. 2019. PMID: 31097454 Free PMC article.
AKT in thyroid tumorigenesis and progression.
Shinohara M, Chung YJ, Saji M, Ringel MD. Shinohara M, et al. Among authors: saji m. Endocrinology. 2007 Mar;148(3):942-7. doi: 10.1210/en.2006-0937. Epub 2006 Aug 31. Endocrinology. 2007. PMID: 16946008 Review.
375 results